Clinical Trial

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

Name: SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC — clinical trial record (NCT06989671)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a Phase II study of anti-nectin-4 ADC combined with the EGFR monoclonal antibody and the PD-1 monoclonal antibody in participants with advanced head and neck squamous cell carcinoma.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-05-16.

Trial Details

NCT Number	NCT06989671
Lead Sponsor	CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions	Head and Neck Squamous Cell Carcinoma
Enrollment	430 participants
Start Date	2025-08-30
Primary Completion	2027-12-30 (estimated)
Study Completion	2028-07-30 (estimated)
Updated on ClinicalTrials.gov	2025-08-27